The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.
Merck (NYSE:MRK) is restructuring its pharmaceutical business into two divisions, Oncology and Specialty/Pharma & Infectious ...
The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming ...
Sales of Merck’s longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts ...
New KEYTRUDA indications are expected to preserve Merck's top line. Click here to read why MRK stock remains a great buy upon ...
Zacks Investment Research on MSN
Merck indicates better growth visibility in post-Keytruda LOE period
Merck MRK announced better-than-expected fourth-quarter 2025 results earlier this month. The company beat estimates for both ...
Merck says Keytruda boosted overall survival in phase 3 ovarian cancer trial and cut death risk in bladder cancer combo data. Read more here.
Merck & Co. said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its blockbuster cancer drug Keytruda for certain patients with ...
KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results